Oncology
Uncovering the Early-Life Roots of Early-Onset Colorectal Cancer
Over the past two decades, colorectal cancer (CRC) epidemiology has undergone a dramatic shift.
Rayan Salih · August 6, 2026 · 7 min
Cancer care and research
Oncology
Practice-changing oncology and hematology research, from early detection through survivorship.
Dr. Abu BakarContributing writer · PharmD, PhD (Pharmacology)
Oncology
Comparative Modeling Reveals Steep Upward Trajectories in Uterine Cancer Through 2050
While mortality rates for most major solid tumors, including breast, lung, and colorectal cancers, have steadily declined over
Rayan Salih · 8 min read
Oncology
Insights from the NCORP Landscape Survey and a Roadmap for Healthcare Providers
A diagnosis of cancer during adolescence or young adulthood disrupts life at a pivotal developmental crossroads.
Rayan Salih · 9 min read
Oncology
GLP-1 Receptor Agonists and Breast Cancer Risk Reduction
The metabolic landscape of oncology is rapidly evolving, driven by an expanding understanding of how systemic metabolic dysfunction
Rayan Salih · 8 min read
Oncology
Overcoming the Post-BTKi Therapeutic Impasse in Mantle Cell Lymphoma
The clinical management of mantle cell lymphoma (MCL) represents one of the most persistent challenges in aggressive B-cell
Rayan Salih · 7 min read
Oncology
Redefining the Postoperative Standard in Head and Neck Cancer: 5-Year Survival and Safety Insights from the JCOG1008 Trial
For oncologists, otolaryngologists, and clinical trialists treating high-risk, locally advanced squamous cell carcinoma of the head and neck
Rayan Salih · 7 min read
Oncology
Redefining the Adjuvant Landscape and Radiation Sequencing in Merkel Cell Carcinoma
For healthcare providers managing cutaneous malignancies, Merkel Cell Carcinoma (MCC) has long represented one of the most formidable
Rayan Salih · 9 min read
Oncology
Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions
For decades, the oncology landscape has viewed lifestyle modification as a pleasant, well-intentioned afterthought—a supportive measure for general
Rayan Salih · 10 min read
Oncology
Shifting Care in Acute Leukemia: The Dawn of Menin Inhibition
For decades, hematologists treating relapsed or refractory (R/R) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) have
Rayan Salih · 10 min read
Oncology
How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC
For years, thoracic oncologists faced a frustrating therapeutic ceiling when treating non-small cell lung cancer (NSCLC) driven by
Rayan Salih · 10 min read
Oncology
Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC
In NSCLC there has been a therapeutic revolution in the management of patients with advanced stage disease, by
Rayan Salih · 10 min read
Oncology
Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC
From Late to Early Intervention: Advanced Prostate Cancer Treatment.
Rayan Salih · 9 min read
Oncology
From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study
The therapeutic landscape for oncogene-addicted non-small cell lung cancer (NSCLC) has shifted dramatically over the past decade.
Rayan Salih · 8 min read
Oncology
Inside the Phase 3 BREAKWATER Trial: First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer
For years, oncology providers have recognized that metastatic colorectal cancer (mCRC) is not a monolithic disease.
Rayan Salih · 9 min read
Oncology
2026 ASCO: Navigating the Era of Adoptive Cellular Therapy and Finite-Duration Regimens in Advanced Malignancies
The landscape of advanced oncology is undergoing an unprecedented structural transition.
Rayan Salih · 9 min read
Oncology
The Early-Onset Cancer Epidemic: A Clinical Briefing on Global Patterns, Biology, and Practice Paradigms
For generations, clinical practice models and medical education have operated under a foundational axiom: cancer is fundamentally a
Rayan Salih · 10 min read
Oncology
Daraxonrasib: Shifting the Paradigm in Metastatic Pancreatic Cancer
For decades, clinicians treating metastatic pancreatic ductal adenocarcinoma (mPDAC) have operated under a somber reality.
Rayan Salih · 8 min read
Oncology
Setidegrasib Shows Early Promise in Advanced Lung and Pancreatic Cancers
Setidegrasib is a new experimental drug that has been formulated to target a mutant version of the KRAS
Dr. Abu Bakar · 7 min read
Oncology
Estradiol Patch Matches Standard Hormone Therapy in Phase 3 Trial: A New First-Line Option for Menopause
This estradiol patch is back in the spotlight following late-phase trial results, which indicate that the efficacy of
Dr. Abu Bakar · 7 min read
Oncology
ctDNA in Early Breast Cancer: Prognostic Power vs Clinical Actionability
Circulating tumor DNA (ctDNA) is a blood-based signal that is drawing a lot of attention in early breast
Dr. Abu Bakar · 6 min read
Oncology
Sunvozertinib Shows Promising First-Line PFS Benefit in EGFR Exon 20 Insertion NSCLC
Sunvozertinib is drawing attention because early reports suggest it may offer progression-free survival benefit as a first-line treatment
Dr. Abu Bakar · 8 min read
Oncology
Sexual Health After Cancer: Why Survivorship Care Must Include Intimacy and Recovery
Sexual health after cancer is often overlooked, yet it is a major part of survivorship care.
Dr. Abu Bakar · 8 min read
Oncology
Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact
For patients with neoadjuvant HER2+ breast cancer, clinicians are increasingly reconsidering whether carboplatin a platinum chemotherapy drug sometimes
Dr. Abu Bakar · 7 min read
Oncology
FDA Approves Pylarify TruVu to Expand PSMA-PET Imaging Access for Prostate Cancer
The Food and Drug Administration has approved the use of Pylarify TruVu, which is an updated version of
Dr. Abu Bakar · 8 min read
Oncology
T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing
Trastuzumab Deruxtecan (T-DXd) is now increasingly emerging as the preferred choice for HER2-low metastatic breast cancer patients, and
Dr. Abu Bakar · 9 min read
Oncology
The Gap Between Cancer Treatment And Survivorship Support
Many people go through cancer treatment and assume that they will return to life’s “new normal,” only to
Dr. Abu Bakar · 7 min read
Oncology
Ultra‑Hypofractionated Radiation Therapy for Locally Advanced Breast Cancer
Shorter, higher‑dose radiation therapy schedules are being explored for people with locally advanced breast cancer, and early experience
Dr. Abu Bakar · 6 min read
Oncology
Matched Sibling Donors Remain the Gold Standard for PTCy‑Based Allogeneic Stem Cell Transplantation
Matched sibling donors remain the top choice for allogeneic hematopoietic cell transplantation (allo-HCT) using post-transplant cyclophosphamide (PTCy) ,
Dr. Abu Bakar · 7 min read
Oncology
Best Late-Line Treatments for Metastatic Colorectal Cancer
For the patient with metastatic colorectal cancer in whom the first- and second-line therapies have failed, difficult decisions
Rayan Salih · 10 min read
Oncology
THP Noninferior To TCbHP For pCR In HER2+ Early Breast Cancer
The comparison of management of HER2-positive early breast cancer suggests that the addition of carboplatin to any backbone
Rayan Salih · 3 min read
Oncology
60% Of Physicians Who Treat Sickle Cell Disease Report Burnout
Sickle cell disease (SCD) is a chronic and potentially life-threatening blood disorder with physical and emotional effects both
Rayan Salih · 10 min read
Oncology
Subtle Early-Onset Cancer (EOC) Burden Rise, Significant Mortality Drop
Cancers diagnosed in younger individuals (early-onset cancer) are reportedly on the rise at the same time that cancer
Rayan Salih · 10 min read
Oncology
Sex Differences Could Shape Future Cancer Immunotherapy
Do sex differences in biology affect how cancer immunotherapies will work in individual patients and how their side
Dr. Abu Bakar · 13 min read
Oncology
The Mechanisms of Resistance: A Deeper Dive into Multimodal Escape in Multiple Myeloma
The newest class of myeloma immunotherapies target a surface protein called GPRC5D.
Rayan Salih · 10 min read
Oncology
FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC
On March 9, 2026, researchers of early stage HER2-positive breast cancer learned more recent information on the development
Rayan Salih · 3 min read
Oncology
Why Breast Cancer Is Increasing In Younger Women, Explained
The growing numbers of young women with breast cancer, means that prevention and screening programs, as well as
Dr. Abu Bakar · 16 min read
Oncology
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
The US Food and Drug Administration (FDA) has approved a new combination treatment for patients with relapsed/refractory multiple
Rayan Salih · 9 min read
Oncology
Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
Why It Matters Mantle cell lymphoma (MCL) is a rare, aggressive B cell non Hodgkin lymphoma (NHL) which
Dr. Abu Bakar · 7 min read
Oncology
Medically-Induced Menopause: Implications for Breast Cancer
Treatment-induced menopause (TIM) is an under-recognized health outcome for women with breast cancer.
Dr. Abu Bakar · 11 min read
Oncology
Medicaid Expansion Prevents Thousands Of Breast Cancer Deaths
Recent analyses and policy conversations point to a clear link between Medicaid expansion and improved outcomes for people
Rayan Salih · 8 min read
One story a day
The story of the day, in your inbox
One health journey each morning — no advice, no alarm, just company for the road.